Overview
Serova Bio designs personalized mRNA cancer vaccines, creating SRV-001 for each patient from their blood and tumor samples. The vaccines use a lipid nanoparticle formulation and are manufactured through partner contract research organizations, with Serova handling patient eligibility, vaccine design, and case management as a full service. Its approach analyzes longitudinal, multi-site tumor data to pick immune targets and tumor-driving mutations, enabling therapies that adapt to tumor evolution and heterogeneity. The company differentiates itself by a data-driven, patient-specific process delivered through a single-patient IND under expanded access, rather than pursuing broad clinical trials, with the goal of delivering tailored immunotherapies for each patient.
Work here?Claim your company
Simplify's take
What believers are saying
- Serova had its first FDA clearance to dose a patient in 2026.
- It has already manufactured vaccines for about a dozen people.
- Octopus Ventures brought Serova into First Cheque II on November 6, 2026.
What critics are saying
- Serova still treats through expanded access, so revenue depends on individual patient exceptions.
- The company has no public randomized data; competitors with clinical trials can outrun it.
- A $200,000 single-patient process limits adoption and can stall commercial scale.
What makes Serova unique
- Serova personalizes SRV-001 from each patient’s blood and tumor samples.
- Its platform analyzes longitudinal, multi-site tumor data to chase evolving tumor-driving mutations.
- It bundles eligibility, design, manufacturing, and case management into one service.
Help us improve and share your feedback! Did you find this helpful?